Published in Biochem J on December 15, 1993
Microbial adherence to and invasion through proteoglycans. Infect Immun (1997) 3.22
Biochemical characterization of the chondroitinase ABC I active site. Biochem J (2005) 0.95
Dermatan sulfate activates nuclear factor-kappab and induces endothelial and circulating intercellular adhesion molecule-1. J Clin Invest (1999) 0.91
Placental dermatan sulfate: isolation, anticoagulant activity, and association with heparin cofactor II. Blood (2005) 0.83
Structural determination of novel tetra- and hexasaccharide sequences isolated from chondroitin sulfate H (oversulfated dermatan sulfate) of hagfish notochord. Glycoconj J (1999) 0.81
Utilization of Glycosaminoglycans/Proteoglycans as Carriers for Targeted Therapy Delivery. Int J Cell Biol (2015) 0.76
Effects of dermatan sulfate derivatives on platelet surface P-selectin expression and protein C activity in blood of inflammatory bowel disease patients. World J Gastroenterol (2004) 0.75
Glycosaminoglycans and their binding to biological macromolecules. Annu Rev Biochem (1978) 4.51
Conformational flexibility: a new concept for explaining binding and biological properties of iduronic acid-containing glycosaminoglycans. Trends Biochem Sci (1988) 1.66
Activation of heparin cofactor II by dermatan sulfate. J Biol Chem (1983) 1.33
Alkaline and smith degradation of oxidized dermatan sulphate-chondroitin sulphate copolymers. Carbohydr Res (1974) 1.32
Periodate oxidation of L-iduronic acid residues in dermatan sulphate. Carbohydr Res (1974) 1.29
Structure of a dermatan sulfate hexasaccharide that binds to heparin cofactor II with high affinity. J Biol Chem (1990) 1.26
Analysis of unsaturated disaccharides from glycosaminoglycuronan by high-performance liquid chromatography. Anal Biochem (1989) 1.12
Nuclear magnetic resonance spectra of heparin in admixture with dermatan sulfate and other glycosaminoglycans. 2-D spectra of the chondroitin sulfates. Carbohydr Res (1989) 1.11
Proteoglycans: an overview. Methods Enzymol (1987) 1.04
Chondroitinase ABC digestion of dermatan sulphate. N.m.r. spectroscopic characterization of the oligo- and poly-saccharides. Biochem J (1989) 0.93
A simple method to measure dermatan sulfate at sub-microgram concentrations in plasma. Thromb Haemost (1988) 0.92
Structural differences of dermatan sulfates from different origins. Carbohydr Res (1986) 0.90
Structural features of dermatan sulfates and their relationship to anticoagulant and antithrombotic activities. Biochem Pharmacol (1991) 0.89
Effects of dermatan sulfate and heparin on inhibition of thrombus growth in vivo. Ann N Y Acad Sci (1989) 0.87
Respective role of antithrombin III and heparin cofactor II in the in vitro anticoagulant effect of heparin and of various sulphated polysaccharides. Br J Haematol (1986) 0.86
The interaction of glycosaminoglycans with heparin cofactor II: structure and activity of a high-affinity dermatan sulfate hexasaccharide. Adv Exp Med Biol (1992) 0.86
Isolation and characterization of dermatan sulfate proteoglycans synthesized by cultured bovine aortic endothelial cells. J Biol Chem (1988) 0.84
Effect of oversulphated chondroitin and dermatan sulphate upon thrombin and factor Xa inactivation by antithrombin III or heparin cofactor II. Biochem J (1988) 0.83
Physicochemical aspects of heparin cofactor II. Ann N Y Acad Sci (1989) 0.82
Assay of dermatan sulfate cofactor (heparin cofactor II) activity in human plasma. Thromb Res (1984) 0.82
Studies on the structural requirements of heparin for the catalysis of thrombin inhibition by heparin cofactor II. Biochim Biophys Acta (1988) 0.82
Failure of aspirin at different doses to modify experimental thrombosis in rats. Thromb Res (1980) 0.81
Isolation of dermatan sulfate with high heparin cofactor II-mediated thrombin-inhibitory activity from porcine spleen. Biochim Biophys Acta (1987) 0.81
1H-n.m.r. investigation of naturally occurring and chemically oversulphated dermatan sulphates. Identification of minor monosaccharide residues. Biochem J (1990) 0.79
[Potentiometry applied to the characterization and analysis of polysaccharides for pharmaceutical use]. Farmaco Prat (1988) 0.78
Plasma anticoagulant mechanisms of heparin, heparan sulfate, and dermatan sulfate. Ann N Y Acad Sci (1989) 0.78
A least-squares method for fitting the Hill equatio to data from several animals. Anal Biochem (1977) 0.77
Antithrombotic properties of a dermatan sulfate hexadecasaccharide fractionated by affinity for heparin cofactor II. Blood (1993) 0.77
Optical coherence tomography in pediatric patients: a feasible technique for diagnosing celiac disease in children with villous atrophy. Dig Liver Dis (2009) 2.69
Minimal sequence in heparin/heparan sulfate required for binding of basic fibroblast growth factor. J Biol Chem (1993) 2.07
Effect of heparin, dermatan sulfate, and related oligo-derivatives on human polymorphonuclear leukocyte functions. J Lab Clin Med (1993) 1.72
Recommendations on biosimilar low-molecular-weight heparins. J Thromb Haemost (2009) 1.68
Conformational flexibility: a new concept for explaining binding and biological properties of iduronic acid-containing glycosaminoglycans. Trends Biochem Sci (1988) 1.66
Structure and biological activity of heparin. Adv Carbohydr Chem Biochem (1985) 1.63
Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochem Biophys Res Commun (1983) 1.62
Effects of pneumoperitoneum and reverse Trendelenburg position on cardiopulmonary function in morbidly obese patients receiving laparoscopic gastric banding. Eur J Anaesthesiol (2000) 1.54
Conformer populations of L-iduronic acid residues in glycosaminoglycan sequences. Carbohydr Res (1990) 1.53
Effect of nitrous oxide on desflurane MACBAR at two target-controlled concentrations of remifentanil. Minerva Anestesiol (2008) 1.48
The effect of adding nitrous oxide on MAC of sevoflurane combined with two target-controlled concentrations of remifentanil in women. Eur J Anaesthesiol (2005) 1.46
The effects of single or multiple injections on the volume of 0.5% ropivacaine required for femoral nerve blockade. Anesth Analg (2001) 1.42
1H and 13C NMR spectral assignments of the major sequences of twelve systematically modified heparin derivatives. Carbohydr Res (1996) 1.41
The structure of heparin oligosaccharide fragments with high anti-(factor Xa) activity containing the minimal antithrombin III-binding sequence. Chemical and 13C nuclear-magnetic-resonance studies. Biochem J (1981) 1.39
Endometriosis of the round ligament: description of a clinical case and review of the literature. Hernia (2005) 1.38
Nerve stimulator and multiple injection technique for upper and lower limb blockade: failure rate, patient acceptance, and neurologic complications. Study Group on Regional Anesthesia. Anesth Analg (1999) 1.25
Controversial glycosaminoglycan conformations. Nature (1986) 1.20
Combined quantitative (1)H and (13)C nuclear magnetic resonance spectroscopy for characterization of heparin preparations. Semin Thromb Hemost (2001) 1.19
Respiratory mechanics in anesthetized paralyzed humans: effects of flow, volume, and time. J Appl Physiol (1985) (1989) 1.18
Small doses of remifentanil or sufentanil for blunting cardiovascular changes induced by tracheal intubation: a double-blind comparison. Eur J Anaesthesiol (2001) 1.17
Small-dose clonidine prolongs postoperative analgesia after sciatic-femoral nerve block with 0.75% ropivacaine for foot surgery. Anesth Analg (2000) 1.16
Integration of foreign DNA in an intergenic region of the archaeon Methanosarcina mazei without effect on transcription of adjacent genes. J Mol Biol (1996) 1.15
Cardiovascular effects of two different regional anaesthetic techniques for unilateral leg surgery. Acta Anaesthesiol Scand (1998) 1.15
Heparin-like compounds prepared by chemical modification of capsular polysaccharide from E. coli K5. Carbohydr Res (1994) 1.13
Hemostatic effects of aprotinin, tranexamic acid and epsilon-aminocaproic acid in primary cardiac surgery. Ann Thorac Surg (1999) 1.12
A double-blind comparison of ropivacaine, bupivacaine, and mepivacaine during sciatic and femoral nerve blockade. Anesth Analg (1998) 1.12
Isolation of new genes in distal Xq28: transcriptional map and identification of a human homologue of the ARD1 N-acetyl transferase of Saccharomyces cerevisiae. Hum Mol Genet (1994) 1.11
A conductimetric method for the determination of sulphate and carboxyl groups in heparin and other mucopolysaccharides. Carbohydr Res (1975) 1.10
Pulmonary and chest wall mechanics in anesthetized paralyzed humans. J Appl Physiol (1985) (1991) 1.09
Mono- and bidimensional 500 MHz 1H-NMR spectra of a synthetic pentasaccharide corresponding to the binding sequence of heparin to antithrombin-III: evidence for conformational peculiarity of the sulfated iduronate residue. Biochem Biophys Res Commun (1985) 1.09
Conformation of heparin pentasaccharide bound to antithrombin III. Biochem J (2001) 1.08
Infected joint replacements in HIV-positive patients with haemophilia. J Bone Joint Surg Br (2001) 1.08
Effect of nasal pressure support ventilation and external PEEP on diaphragmatic activity in patients with severe stable COPD. Chest (1993) 1.06
Target-controlled infusion during monitored anesthesia care in patients undergoing EUS: propofol alone versus midazolam plus propofol. A prospective double-blind randomised controlled trial. Dig Liver Dis (2006) 1.06
Ropivacaine or 2% mepivacaine for lower limb peripheral nerve blocks. Study Group on Orthopedic Anesthesia of the Italian Society of Anesthesia, Analgesia, and Intensive Care. Anesthesiology (1999) 1.04
Regional cerebral metabolism of glucose in comatose and vegetative state patients. J Neurosurg Anesthesiol (1995) 1.04
Interscalene brachial plexus anaesthesia with 0.5%, 0.75% or 1% ropivacaine: a double-blind comparison with 2% mepivacaine. Br J Anaesth (1999) 1.03
Anti-Xa active heparin oligosaccharides. Thromb Res (1980) 1.03
Eleven X chromosome breakpoints associated with premature ovarian failure (POF) map to a 15-Mb YAC contig spanning Xq21. Genomics (1997) 1.01
Cardiorespiratory changes during gynaecological laparoscopy by abdominal wall elevation: comparison with carbon dioxide pneumoperitoneum. Br J Anaesth (1997) 0.99
Results of the representative Italian national survey on radon indoors. Health Phys (1996) 0.98
Transcriptional organization of a 450-kb region of the human X chromosome in Xq28. Proc Natl Acad Sci U S A (1993) 0.98
Activation of coagulation and fibrinolysis during coronary surgery: on-pump versus off-pump techniques. Anesthesiology (2001) 0.96
Midazolam and pethidine versus propofol and fentanyl patient controlled sedation/analgesia for upper gastrointestinal tract ultrasound endoscopy: a prospective randomized controlled trial. Dig Liver Dis (2007) 0.95
Frequency of hypotension during conventional or asymmetric hyperbaric spinal block. Reg Anesth Pain Med (1999) 0.95
Structural characterization of low molecular weight heparins. Semin Thromb Hemost (1999) 0.94
Biosynthesis of heparin. Availability of glucosaminyl 3-O-sulfation sites. J Biol Chem (1990) 0.93
Specific antibodies to diphtheria toxin and type 6A pneumococcal capsular polysaccharide induced by a model of semi-synthetic glycoconjugate antigen. Mol Immunol (1985) 0.93
Fentanyl does not improve the nerve block characteristics of axillary brachial plexus anaesthesia performed with ropivacaine. Acta Anaesthesiol Scand (2001) 0.93
Separation and determination of cobalamins on an SP-Sephadex column. J Chromatogr (1971) 0.92
Effect of substitution pattern on 1H, 13C NMR chemical shifts and 1J(CH) coupling constants in heparin derivatives. Carbohydr Res (2000) 0.92
Respiratory mechanics during submersion and negative-pressure breathing. J Appl Physiol (1966) 0.92
Clinical assessment of target-controlled infusion of propofol during monitored anesthesia care. Can J Anaesth (1999) 0.92
Pulmonary function changes after interscalene brachial plexus anesthesia with 0.5% and 0.75% ropivacaine: a double-blinded comparison with 2% mepivacaine. Anesth Analg (1999) 0.92
Antibodies to recombinant human tissue-transglutaminase in coeliac disease: diagnostic effectiveness and decline pattern after gluten-free diet. Dig Liver Dis (2005) 0.91
Relationship between plasma antifactor Xa activity and the antithrombotic activity of heparins of different molecular mass. Haemostasis (1996) 0.90
Arterial to end-tidal carbon dioxide gradient and physiological dead space monitoring during general anaesthesia: effects of patients' position. Minerva Anestesiol (1997) 0.90
End tidal carbon dioxide monitoring in spontaneously breathing, nonintubated patients. A clinical comparison between conventional sidestream and microstream capnometers. Minerva Anestesiol (2001) 0.90
Does speed of intrathecal injection affect the distribution of 0.5% hyperbaric bupivacaine? Br J Anaesth (1998) 0.90
Regional anaesthesia for outpatient knee arthroscopy: a randomized clinical comparison of two different anaesthetic techniques. Acta Anaesthesiol Scand (2000) 0.89
Structural features of dermatan sulfates and their relationship to anticoagulant and antithrombotic activities. Biochem Pharmacol (1991) 0.89
Tranexamic acid compared with high-dose aprotinin in primary elective heart operations: effects on perioperative bleeding and allogeneic transfusions. J Thorac Cardiovasc Surg (2000) 0.89
Motional properties of E. coli polysaccharide K5 in aqueous solution analyzed by NMR relaxation measurements. Carbohydr Res (1997) 0.88
Toward a biotechnological heparin through combined chemical and enzymatic modification of the Escherichia coli K5 polysaccharide. Semin Thromb Hemost (2001) 0.88
Dynamics in aqueous solutions of the pentasaccharide corresponding to the binding site of heparin for antithrombin III studied by NMR relaxation measurements. Carbohydr Res (1995) 0.88
Different anesthesiological management in two high risk pregnant women with heart failure undergoing emergency cesarean section. Minerva Anestesiol (2005) 0.88
Synthesis of heparin fragments: a methyl alpha-pentaoside with high affinity for antithrombin III. Carbohydr Res (1987) 0.86
In vitro antiplasmodial activity of extracts of Tristaniopsis species and identification of the active constituents: ellagic acid and 3,4,5-trimethoxyphenyl-(6'-O-galloyl)-O-beta-D-glucopyranoside. J Nat Prod (2001) 0.86
A clinical comparison of ropivacaine 0.75%, ropivacaine 1% or bupivacaine 0.5% for interscalene brachial plexus anaesthesia. Eur J Anaesthesiol (1999) 0.86
Uptake and elimination of enflurane in man. A comparative study between enflurane and halothane. Br J Anaesth (1972) 0.86
Randomized comparison between sevoflurane anaesthesia and unilateral spinal anaesthesia in elderly patients undergoing orthopaedic surgery. Eur J Anaesthesiol (2003) 0.86
"Supersulfated" heparin fragments, a new type of low-molecular weight heparin. Physico-chemical and pharmacological properties. Biochem Pharmacol (1987) 0.86
Correlation between structure, fat-clearing and anticoagulant properties of heparins and heparan sulphates. Arzneimittelforschung (1983) 0.86
Molecular phylogeography of the asp viper Vipera aspis (Linnaeus, 1758) in Italy: evidence for introgressive hybridization and mitochondrial DNA capture. Mol Phylogenet Evol (2009) 0.86
Structure of heparin-derived tetrasaccharide complexed to the plasma protein antithrombin derived from NOEs, J-couplings and chemical shifts. Eur J Biochem (1999) 0.86
Effect of GPIIb-IIIa complex ligands on calcium ion movement and cytoskeleton organization in activated platelets. Biochem Biophys Res Commun (1988) 0.86
Effects of demethylfruticuline A and fruticuline A from Salvia corrugata Vahl. on biofilm production in vitro by multiresistant strains of Staphylococcus aureus, Staphylococcus epidermidis and Enterococcus faecalis. Int J Antimicrob Agents (2010) 0.86
Hypothermia prevention and treatment. Anaesthesia (1998) 0.86
Conformations of the major residues in heparin. H-NMR sepctroscopic studies. Biochem Biophys Res Commun (1978) 0.86